This site is intended for Healthcare professionals only.

Risky to attempt SAVR within 3 months of a stroke : Study

Risky to attempt SAVR within 3 months of a stroke : Study

The previous stroke is a major risk factor for recurrent ischemic stroke and major adverse cardiac event (MACE) in patients undergoing surgical aortic valve replacement (SAVR), especially if the time elapsed between previous stroke and surgery is less than 3 months, suggests a study published in the journal JAMA Cardiology

The study was conducted by Charlotte Andreasen, Copenhagen University Hospital, Hellerup, Denmark, and colleagues, with an objective to evaluate the association of time elapsed between previous stroke and SAVR with the risk of recurrent perioperative stroke, MACE, and mortality among patients with aortic valve stenosis.

SAVR is a surgery done for replacement of an aortic valve in conditions of aortic valve stenosis and aortic valve regurgitation. During this surgery, the damaged valve is removed and replaced with an artificial valve. The valve replacement is typically an open-heart surgery.

Progression of aortic valve stenosis is medically unpreventable. Likewise, the mortality rate among severely symptomatic patients is markedly increased unless aortic valve replacement is performed. Ischemic stroke is a feared complication of SAVR and prior stroke is a well-established risk factor for periprocedural stroke. Recurrent stroke is associated with more severe functional disability, greater financial burden, and increased mortality compared with an incident stroke. Consequently, it is of particular relevance to investigate the association of time elapsed between previous stroke and SAVR with the risk of adverse outcomes in patients with aortic valve stenosis.

For carrying out the cohort study, the researchers used data from Danish administrative registries and included all patients with aortic valve stenosis older than 18 years who underwent SAVR between 1996 and 2014 (n = 14 030). Patients who received simultaneous mitral, tricuspid, or pulmonary valve surgery and patients with endocarditis 1 year prior to surgery were excluded.

Based on the study, the researchers found out that the rate of SAVR-related ischemic stroke was about 18% in that early period after a prior stroke, compared with 1.2% for patients without prior stroke. This corresponded to a 14-fold jump in adjusted risk. That compared to only a 2-fold to 4-fold risk increase for SAVR performed later than 3 months after a stroke, reported investigators in Denmark based on their nationwide 14,000-patient cohort study. The risk for major adverse cardiac events (MACE: acute MI, ischemic stroke, or cardiovascular death) related to SAVR, meaning within 30 days of the procedure, followed a similar time pattern.

But prior stroke showed no associations with death from any cause or cardiovascular causes within 30 days of SAVR.

“Therefore, the data suggest that the increased risk of MACE was mainly driven by the increased risk of stroke,” Dr. Andreasen told | Medscape Cardiology.

The findings suggest that any SAVR that is needed after a stroke be delayed for at least 3 or 4 months if possible, to reduce the risk of recurrent stroke.

Delaying it longer could potentially lower the risk even further, but importantly, “the mortality rate among severely symptomatic patients is known to be markedly increased unless aortic valve replacement is performed, and for critically ill patients, postponement may not be an option,” said Andreasen.

For further information click on the link: 10.1001/jamacardio.2018.0899


The following two tabs change content below.
Medha Baranwal

Medha Baranwal

Medha Baranwal joined Medical Dialogues as a Desk Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She can be contacted at Contact no. 011-43720751
Source: With inputs from JAMA Cardiology

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted